Skip to content

Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our privacy policy.

Treat to Target in
Crohn's Disease

Drive Efficiency

Improve Patient
Experience

GIQuant® provides a clinically validated, objective disease activity score for small bowel Crohn’s disease based on intestinal motility.

The GIQuant® score is measured at the site of active disease and changes in response to disease activity.

GIQuant® works with DICOM viewers and routine
MRI protocols and is CE Marked for use in adults and children with known or suspected small bowel Crohn’s Disease.

Normal Terminal Ileal motility

High GIQuant® score at Terminal Ileum (red ROI)

 

Active Disease at Terminal Ileum

Low GIQuant® score at Terminal Ileum (red ROI)

GIQuant® can track disease response to a range of interventions objectively, this may lead to a reduction in time on ineffective therapies.

GIQuant® allows for disease activity analysis without the need for IV gadolinium and can process historic data to see patient motility over time.

GIQuant® is validated with both breath-hold and free breathing dynamic MRI data.

Towards personalised treatment for
Crohn’s Disease patients

Precision medicine is about ensuring the right patient gets the right medication at the right time. We’re not there yet with Crohn’s Disease. The figure above demonstrates how some patients may (red line) stop responding in biological therapy and we may not know for months or even years.
 
This wastes money, it’s frustrating for the patient and the clinician and of course the disease continues to get worse.
 
If we can track response closely and objectively we can identify times where medications stop work and make a change, optimising their treatment. Recent studies have shown the power of this approach with Faecal Calprotectin in the CALM study. GIQuant can be used in a similar way specifically in the small intestine MRE data to look for early signs of improvement.
 
When a patient presents with a flare, their GIQuant score is likely to be low. They’ll be started on anti-inflammatory medications and, where the treatment is successful, their GIQuant score will usually increase.  The GIQuant score can be quoted from routine MRE data alongside the routine tests providing a supplementary, quantitative input for the gastroenterologists treatment plan.
 
GIQuant does not replace the routine MRE exam or an experienced Radiologist but it does not need gadolinium or a spasmolytic. GIQuant can be used in a shorter, follow up scan potentially at an earlier date to examine treatment response and get the patient on the right track sooner.

low

1. Plumb A. et al. (2015) Magnetic resonance imaging-quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn’s disease. Allimnt Pharmcol Ther. doi: 10.11111/apt. 13275

2. Colombel JF. (2017) Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet.  390: 2779-2789

3. Menys A. et al. (2018). Quantified Terminal Ileal Motility during MR Enterography as a Biomarker of Crohn Disease Activity: Prospective Multi-Institution Study. Radiology. 289(2):428‐435. doi:10.1148/radiol.2018180100

FAQs

Yes, as all patient data is processed on premises at the hospital. There is no cloud and no external data transfer.

No, GIQuant and its results are designed to work with your existing PACS infrastructure.

Yes, it is possible to process historic patient MRE scan data and extract GIQuant scores.


Read more at Menys A. et al. (2018). Quantified Terminal Ileal Motility during MR Enterography as a Biomarker of Crohn Disease Activity: Prospective Multi-Institution Study. Radiology. 289(2):428‐435. doi:10.1148/radiol.2018180100

Yes GIQuant is DICOM compliant and designed and developed to fit seamlessly within existing workflows

Yes. GIQuant requires motility MRI to produce a score along with an optimal set of acquisition parameters (i.e. 20 second breath hold).

Intestinal motility is a reactively new parameter that looks at the physiology of the intestine (how it is moving) in a complementary way to the structure of the intestine (bowel wall thickening) as seen on T2.

It has the added benefit of not requiring IV contrast or a spasmolytic (e.g. Buscopan)

GIQuant has been designed to integrate seamlessly within existing routine workflows through the implementation of customisable configuration at installation.

Radiologist – GIQuant is already installed within your hospital PACS and the appropriate data is auto-routed without you having to do anything. When GIQuant has finished, the derived data will be returned to that subjects session. Results may be annotated, and values quoted in my typical reporting process.

Gastroenterologist – During a consultation with a patient you would take into account the radiology report and the GIQuant score in comparing how the patient is responding to treatment. In some cases, it may be useful to access the results directly and talk the patient through their situation using the GIQuant results (and MRE in general) to help illustrate findings. 

GIQuant is CE marked (Class 2a) for use in adults and children for patients with, or suspected of, small bowel Crohn’s disease. THE PRODUCT IS NOT FDA 510(K) APPROVED, and NOT FOR SALE IN THE U.S..

GIQuant has been designed and developed by Motilent to globally recognised manufacturing standards. Motilent is ISO 13485 2016 certified.

Yes, GIQuant is only indicated for use with small bowel MRI data.

Generally, MRI shows high specificity and sensitivity for small bowel disease and this is why we have focused on this area inline with the optimal use case of the MRE test.

GIQuant has comparable performance to the widely accepted clinical trial endpoint MaRIA as well as a strong association with, endoscopic (CDEIS) and histopathological (eAIS) measures of disease activity.

More can be read at:

Menys A. et al. (2018). Quantified Terminal Ileal Motility during MR Enterography as a Biomarker of Crohn Disease Activity: Prospective Multi-Institution Study. Radiology. 289(2):428‐435. doi:10.1148/radiol.2018180100